- Home
- YORW vs CRVS Comparison
YORW vs CRVS Comparison
Compare YORW & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YORW
- CRVS
- Stock Information
- Founded
- YORW 1816
- CRVS 2014
- Country
- YORW United States
- CRVS United States
- Employees
- YORW N/A
- CRVS N/A
- Industry
- YORW Water Supply
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- YORW Utilities
- CRVS Health Care
- Exchange
- YORW Nasdaq
- CRVS Nasdaq
- Market Cap
- YORW 433.6M
- CRVS 459.0M
- IPO Year
- YORW N/A
- CRVS 2016
- Fundamental
- Price
- YORW $32.36
- CRVS $7.61
- Analyst Decision
- YORW
- CRVS Strong Buy
- Analyst Count
- YORW 0
- CRVS 4
- Target Price
- YORW N/A
- CRVS $13.75
- AVG Volume (30 Days)
- YORW 88.1K
- CRVS 1.1M
- Earning Date
- YORW 11-05-2025
- CRVS 11-11-2025
- Dividend Yield
- YORW 2.74%
- CRVS N/A
- EPS Growth
- YORW N/A
- CRVS N/A
- EPS
- YORW 1.37
- CRVS N/A
- Revenue
- YORW $76,236,000.00
- CRVS N/A
- Revenue This Year
- YORW $7.50
- CRVS N/A
- Revenue Next Year
- YORW $6.33
- CRVS N/A
- P/E Ratio
- YORW $23.82
- CRVS N/A
- Revenue Growth
- YORW 4.09
- CRVS N/A
- 52 Week Low
- YORW $29.68
- CRVS $2.54
- 52 Week High
- YORW $38.50
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- YORW 61.60
- CRVS 61.71
- Support Level
- YORW $31.59
- CRVS $6.81
- Resistance Level
- YORW $32.79
- CRVS $7.96
- Average True Range (ATR)
- YORW 0.66
- CRVS 0.50
- MACD
- YORW 0.16
- CRVS -0.01
- Stochastic Oscillator
- YORW 82.87
- CRVS 81.67
About YORW York Water Company (The)
The York Water Co is an investor-owned water utility company in the United States. The primary business of the company is to impound, purify to meet or exceed safe drinking water standards and distribute water. It also owns and operates three wastewater collection systems and eleven wastewater collection and treatment systems. The company operates within its franchised territory, which covers more than 57 municipalities within four counties in south-central Pennsylvania.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).